Table 3. Focused miRNA panel – miRNAs significantly associated with overall survival.
Screening CAPEOXBEV cohort | Validation CAPEOXBEV cohort | Combined CAPEOXBEV cohort | Control CAPEOX cohort | Interactiona | |||||||||||
n = 155 | n = 121 | n = 276 | n = 127 | all | distal | proximal | |||||||||
miRNA | HRb | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | P | P | P |
Raw expression values | |||||||||||||||
miR-15a-5p | 0.80 | 0.65–0.99 | 0.04 | 0.87 | 0.66–1.16 | 0.34 | 0.81 | 0.69–0.97 | 0.02 | 1.05 | 0.83–1.34 | 0.68 | 0.31 | 0.41 | 0.74 |
miR-196b-5p | 0.83 | 0.69–1.01 | 0.06 | 0.66 | 0.50–0.87 | 0.003 | 0.77 | 0.66–0.90 | 0.0008 | 0.78 | 0.62–0.98 | 0.04 | 0.20 | 0.06 | 0.23 |
miR-204-5p | 0.76 | 0.64–0.91 | 0.003 | 0.88 | 0.66–1.18 | 0.38 | 0.77 | 0.64–0.93 | 0.005 | 1.02 | 0.81–1.28 | 0.87 | 0.94 | 0.80 | 0.54 |
miR-338-3p | 0.81 | 0.65–1.00 | 0.045 | 0.93 | 0.70–1.24 | 0.63 | 0.85 | 0.72–1.01 | 0.07 | 1.01 | 0.80–1.27 | 0.92 | 0.52 | 0.40 | 0.68 |
miR-545-3p | 0.85 | 0.74–0.98 | 0.03 | 0.95 | 0.80–1.12 | 0.53 | 0.90 | 0.81–1.01 | 0.06 | 1.06 | 0.95–1.19 | 0.30 | 0.39 | 0.39 | 0.45 |
miR-552 | 0.77 | 0.61–0.96 | 0.02 | 0.93 | 0.68–1.27 | 0.63 | 0.77 | 0.63–0.95 | 0.01 | 1.02 | 0.80–1.31 | 0.85 | 0.44 | 0.29 | 0.76 |
miR-592 | 0.69 | 0.69–0.92 | 0.01 | 0.76 | 0.60–0.95 | 0.01 | 0.73 | 0.62–0.86 | 0.0001 | 0.76 | 0.55–1.05 | 0.10 | 0.31 | 0.33 | 0.85 |
miR-664-3p | 0.64 | 0.48–0.86 | 0.003 | 0.60 | 0.44–0.82 | 0.002 | 0.61 | 0.49–0.75 | <0.0001 | 0.85 | 0.61–1.17 | 0.31 | 0.02 | 0.03 | 0.50 |
Mean-normalized expression values | |||||||||||||||
miR-1 | 1.01 | 0.77–1.32 | 0.96 | 1.19 | 0.84–1.69 | 0.32 | 1.08 | 0.87–1.32 | 0.49 | 1.36 | 1.02–1.82 | 0.04 | 0.98 | 0.82 | 0.75 |
miR-155-5p | 1.31 | 1.03–1.67 | 0.03 | 1.21 | 0.91–1.61 | 0.19 | 1.23 | 1.03–1.47 | 0.03 | 0.96 | 0.75–1.23 | 0.76 | 0.38 | 0.70 | 0.30 |
miR-185-5p | 1.49 | 1.18–1.88 | 0.0008 | 1.23 | 0.89–1.72 | 0.21 | 1.34 | 1.12–1.60 | 0.001 | 0.91 | 0.70–1.18 | 0.46 | 0.09 | 0.23 | 0.57 |
miR-196b-5p | 0.89 | 0.67–1.18 | 0.43 | 0.70 | 0.51–0.96 | 0.03 | 0.79 | 0.64–0.97 | 0.03 | 0.73 | 0.58–0.93 | 0.01 | 0.99 | 0.43 | 0.09 |
miR-204-5p | 0.75 | 0.61–0.93 | 0.009 | 0.95 | 0.70–1.28 | 0.71 | 0.85 | 0.72–1.01 | 0.06 | 1.01 | 0.85–1.21 | 0.89 | 0.43 | 0.61 | 0.40 |
miR-455-5p | 1.19 | 0.95–1.49 | 0.14 | 1.27 | 1.03–1.56 | 0.03 | 1.24 | 1.06–1.45 | 0.007 | 0.99 | 0.85–1.15 | 0.91 | 0.02 | 0.19 | 0.38 |
miR-592 | 0.77 | 0.59–1.00 | 0.05 | 0.76 | 0.63–0.93 | 0.007 | 0.77 | 0.66–0.89 | 0.0004 | 0.71 | 0.53–0.96 | 0.03 | 0.52 | 0.21 | 0.35 |
miR-664-3p | 0.66 | 0.49–0.91 | 0.01 | 0.55 | 0.39–0.79 | 0.001 | 0.60 | 0.48–0.76 | <0.0001 | 0.81 | 0.59–1.11 | 0.18 | 0.02 | 0.02 | 0.45 |
Interaction was tested for all patients and for patients with distal (sigmoid to rectum) and proximal (cecum to descending colon) primary tumor location separately.
Hazard ratio is per inter-quartile range expression increase and is adjusted for age, sex, number of metastatic sites, prior adjuvant treatment and primary tumor location.
Abbreviations: HR, hazard ratio; CI, confidence interval.